XML 76 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Collaboration Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Apr. 30, 2021
USD ($)
Aug. 31, 2020
USD ($)
Program
Oct. 31, 2018
Program
Jun. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Proceeds from fees received           $ 14,000,000.0      
Accounts receivable current, research extension fee           2,000,000.0      
Contract asset, research extension fee           8,000,000.0      
Receivable research extension fee           24,000,000.0      
2018 Gilead Agreement [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Research term     3 years            
Number of licensed product | Program     5            
Non-refundable upfront payment received           50,000,000.0   $ 50,000,000.0  
Milestone payments receivable               $ 1,700,000,000  
Gilead Letter Agreement [Member] | License Revenue [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Contract with customer liability, revenue recognized             $ 700,000    
Amended Gilead Agreement [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Research term   7 years              
Number of licensed product | Program   15              
Non-refundable upfront payment received           125,000,000.0      
Milestone payments receivable   $ 410,000,000.0              
Temporary equity, par value   125,000,000.0              
Revenue recognized, cumulative catch-up adjustment         $ (11,300,000)        
Research extension fee             12,000,000.0   $ 12,000,000.0
Research extension fees, variable consideration           $ 12,000,000.0      
Contract with customer liability, revenue recognized       $ 11,000,000.0          
License fee amount $ 11,000,000.0                
Amended Gilead Agreement [Member] | Minimum [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Equity method investment, ownership percentage           10.00%      
Amended Gilead Agreement [Member] | Series B-1 Preferred Stock [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Temporary equity, par value   $ 20,000,000.0              
Gilead Agreement [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Transaction price allocated to performance obligation           $ 199,000,000.0      
Short-term deferred revenue           26,000,000.0 32,000,000.0    
Long-term deferred revenue           114,700,000 120,800,000    
Gilead Agreement [Member] | Collaboration Revenue [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Contract with customer liability, revenue recognized           26,000,000.0 $ 7,000,000.0    
Gilead Agreement Based Performance [Member] | License Revenue [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
License fee amount received, recognized as revenue           $ 11,000,000.0